Cell differenctiation using non-integrating lenviral vectors

Cell therapy applications could benefit from the transient expression of differentiation factors. LentiFlash has shown to be particularly effective in the ability to trigger a shift in cell fate by expressing two transcription factors involved in osteoblastic differentiation.

Lineage commitment for cell therapy

RUNX2 and  DLX5  are master transcription factors inducing skeletogenesis in mesenchymal stem cells.

DLX5 has been implicated in the commitment of mesenchymal progenitors to the osteoblast lineage by the upregulation of RUNX2RUNX2 is considered essential for osteoblastic differentiation.

LentiFlash cell differentiation

Figure 4 shows lineage commitment in highly immature MSC-like cells toward an early osteoblastic lineage stage.

We first looked at the mRNA levels of transcription factors RUNX2 and DLX5 (induced by LentiFlash particles). At 58 h post-transduction, endogenous genomic RUNX2 or DLX5 mRNA levels significantly increased. In addition, the osteoblastic marker integrin-bone sialo-protein (iBSP) was upregulated in both conditions suggesting a commitment of MSC-l toward an early osteoblastic lineage stage.

LentiFlash can be used for many other applications. Please contact us for your cell differentiation project with your target cells and fill out the form with the information you are willing to share with us.